| Document |
Document Title |
|
WO/2008/077188A1 |
The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administer...
|
|
WO/2008/077625A1 |
The present invention relates to heterocyclyl- substituted-ethylamino- phenyl compounds of general formula (I), wherein K-L-M-N, Z and R1, R2, R3,R4 are as described in the claims methods for their preparation, medicaments comprising the...
|
|
WO/2008/079339A2 |
The present invention pertains, at least in part, to a substituted tetracycline compound of Formula (I): wherein X is CHC(R13VY), CR6 R6, C=CR6 R6, S, NR6, or O; E is NR7dR7β, OR7f or (CH2)o.iC(=W)WR7s; W is O, S, NR711 or CR75R7*; W is...
|
|
WO/2008/078674A1 |
Disclosed is a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof, wherein a carbon atom having an asterisk has an R-configuration; R1 and R2 independently represent a hydrogen atom, a halogen atom, an ...
|
|
WO/2008/066131A1 |
Disclosed is a compound represented by the formula (I) below, which has GPR120 agonist activity and thus is useful for treatment of diabetes or hyperlipemia, or a pharmaceutically acceptable salt thereof. (In the formula, (AA) represents...
|
|
WO/2008/062044A1 |
The invention relates to novel cyclic compounds of the formula (I), in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
|
|
WO/2008/060569A1 |
One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit BcI function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention...
|
|
WO/2008/059023A1 |
The present invention relates to novel compounds of formula [I], wherein R1 represernts heteroaryl, at least one substituent among R5, R6 and R7 represent -SR12, -S(O)R12 or -S(O)2R12 and the remaining substituents are as defined in the ...
|
|
WO/2008/057280A1 |
The present invention relates to compounds of Formulas I and II, wherein B1, B2, B3, B4, C1, C2, ring D, L1, L2 and R1-4 are defined herein, synthetic intermediates, and pharmaceutical compositions, comprising such compounds. The compoun...
|
|
WO/2008/057775A2 |
A compound of Formula I and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with th...
|
|
WO/2008/053326A1 |
The present invention relates to oxalate salt of the compound of formula (I) in all its stereochemical configurations, a process for its preparation and its use in treating mood disorders, disorders of anxiety, depression and convulsive ...
|
|
WO/2008/053325A1 |
The present invention relates to fumarate salt of the Compound of formula (I) in all its stereochemical configurations, a process for its preparation and its use in treating mood disorders, disorders of anxiety, depression and convulsive...
|
|
WO/2008/050167A1 |
The present invention relates to new sulfonamide derivatives of formula (I), wherein R1-R8 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective a...
|
|
WO/2008/046072A2 |
The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain...
|
|
WO/2008/043263A1 |
A series of isoxazole derivatives and methods of treating immune-mediated diseases by isoxazole derivatives are described.
|
|
WO/2008/044767A1 |
Disclosed is a novel SCD inhibitor. The SCD inhibitor comprises a compound represented by the formula [I], a salt thereof, or a prodrug of the compound or the salt. wherein the ring A represents an aromatic ring which may be substituted;...
|
|
WO/2008/039645A1 |
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...
|
|
WO/2008/036642A2 |
The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
|
|
WO/2008/036653A2 |
The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
|
|
WO/2008/036652A2 |
The present invention is directed to amidino heterocyclic compounds of formula Ia and IIa which are modulators of indoleamine 2, 3 - dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
|
|
WO/2008/030618A1 |
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L1, ℗, L2, M, X, L3, and A are provided h...
|
|
WO/2008/030520A1 |
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention als...
|
|
WO/2008/025694A1 |
The present invention relates to compounds of the general formula I wherein R1 is lower alkyl, aryl or heteroaryl, wherein aryl and heteroaryl are optionally substituted by halogen, lower alkyl, lower alkoxy, lower alkyl substituted by h...
|
|
WO/2008/026217A1 |
A process for preparation of 1,2-benzisoxazole-3-acetic acid reacting 4-hydroxy coumarin and hydroxylamine in water according to the following scheme of reaction. Formula (I).
|
|
WO/2008/022938A1 |
The present invention relates to compounds of the general Formula (I) wherein (A) is a 5 or 6-membered aromatic or heteroaromatic ring; R1 is cycloalkyl or is aryl or heteroaryl, wherein at least one ring is aromatic in nature, unsubstit...
|
|
WO/2008/023157A1 |
A compound of formula (I): Formula (I) having M3 receptor- antagonist activity or having both muscarinic receptor antagonist and β2-agonist activity; a composition comprising such a compound; the use of such a compound in therapy (such ...
|
|
WO/2008/024337A2 |
The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit BcI function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
|
|
WO/2008/020007A2 |
A process for the preparation of for the preparation of 5-hydroxyisoxazolidines, 5- isoxazo lidinones, β-amino acids, β-amino aldehydes and derivatives thereof, by reacting hydroxyl amines or hydroxyl carbamates with an α,β-unsaturat...
|
|
WO/2008/016692A2 |
The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activate...
|
|
WO/2008/012027A1 |
A compound of formula (I):wherein A1, A2, A3, A4, R1, R2, R3, R4, G1, G2, Q1, Y1, Y2, Y3 and Y4 are as defined in claim 1; or salts or N-oxides thereof. Furthermore, the present invention relates to processes and intermediates for prepar...
|
|
WO/2008/014199A2 |
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...
|
|
WO/2008/011080A2 |
The present invention comprises a new class of compounds capable of modulating the c-kit protein kinase and, accordingly, useful for treatment of c-kit mediated diseases including, without limitation, autoimmune disease, allergies, masto...
|
|
WO/2008/011110A2 |
The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various fibrotic and mast cell related diseases such as mastoc...
|
|
WO/2008/009695A1 |
The present invention refers to a process for rearranging a spirolactam (I) under acidic conditions to yield an oxabicyclo [4.3.0] none (II) or (III) or a 1-aza-2oxaspiro derivative (IV). The present invention also refers said oxabicyclo...
|
|
WO/2008/006561A1 |
The invention relates to substituted isoxazolines according to the general formula (I) : in which A, R1, R2, R3, R4, Z, X, m, n, and p, are given in the claims, and salts thereof, to pharmaceutical compositions comprising said substitute...
|
|
WO/2008/003141A1 |
Substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity; or derivatives thereof, analogues thereof, pharmaceutically acceptable salts thereof, and metabolites thereof; with the proviso that the compound is not Tran...
|
|
WO2007118323B1 |
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type or T-type calcium channel activity are disclosed. Specifically, a series of isoxazole containing ...
|
|
WO/2007/145835A2 |
Benzamide derivatives of formula ( I ) are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders, formula (I), wherein R1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, and n...
|
|
WO/2007/141269A1 |
The present invention relates to novel isoxazole derivatives of formula (I) which bind to the P2X7 receptor and are capable of interfering with the effects of ATP at the P2X7 receptor: and the use of such compounds or pharmaceutical comp...
|
|
WO/2007/137954A1 |
The present invention is concerned with aryl-4-ethynyl-isoxazole derivatives of formula (I) wherein R1 to R5 are as described in the specification, R5 representing an optionally substituted aryl or heteroaryl. It has been found that this...
|
|
WO/2007/137980A1 |
Endothelin receptor antagonist nitroderivatives of general formula (I) having an improved pharmacological activity compared with their parent compounds. They can be employed for treating or preventing endothelial-related disorders, renal...
|
|
WO/2007/138996A1 |
Disclosed is a crystal of 3-[5-[4-(cyclopentyloxy)-2- hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6- yl)methoxy]phenyl]propionic acid having refraction angles of 14.0, 16.0, 23.3, 23.7 and 26.3˚ as measured in terms of 2θ in powder ...
|
|
WO/2007/129019A1 |
The present invention relates to compounds of formula (I) that mediate Edg, including Edg-1, 1 processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to thei...
|
|
WO/2007/125952A1 |
Disclosed is a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, or a solvate of any of them. (I) In the formula, R1 represents an optionally substituted lower alkyl group; Y represents -S(O)n- (w...
|
|
WO/2007/125984A1 |
[PROBLEMS] To provide a novel pest-controlling agent, particularly an agricultural and horticultural insecticide, which is effective against pests having resistance to already-existing pesticides and which is suitable for labor-saving ap...
|
|
WO/2007/116374A1 |
The invention relates to sulfonamide compounds of formula (I), where A, B, R3 and R4 are as defined in the claims, and their use as orexin receptor antagonists in the prevention and treatment of eating and drinking disorders, all types o...
|
|
WO/2007/114124A1 |
Disclosed is a compound represented by the formula below, a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt, which is useful as an inhibitor of 11β-hydroxysteroid dehydrogenase type I. wherein R1 repres...
|
|
WO/2007/110237A2 |
Compounds of Formula (I) wherein R1 is aryl, cyclohexyl or heterocyclyl, or (C1-4)alkyl substituted by aryl, cyclohexyl or heterocyclyl, R2 is defined heterocyclyl, R3 is alkyl, aryl, cyclohexyl or heterocyclyl, or (C1-4)alkyl substitute...
|
|
WO/2007/110068A2 |
The invention relates to novel isooxazole derivatives which are suitable for producing pharmaceutical compositions.
|
|
WO/2007/111921A1 |
Diaza heterocyclic amide derivatives according to Formula (I) have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: (I) where R5,R6,R7,R8,R9,R10, m, Q, X, and Y are set forth i...
|
